Tessellate BIO’s Post

View organization page for Tessellate BIO, graphic

1,220 followers

The American Association for Cancer Research annual meeting 5-10 April in San Diego is a big event for Tessellate BIO! Our senior leadership team and key R&D team members are attending to learn, network and share updates on how we are creating the next generation Synthetic Lethality precision oncology company.   We are redefining Synthetic Lethality in cancer beyond homologous recombination deficiency, turning cancer patients into cancer survivors. Our approach is to identify novel targets and treat cancers in a selective manner, using a combination of proprietary targets and dedicated diagnostic assays. We are building a first in class pipeline by exploiting synthetic lethal targets in DNA damage response (#DDR) pathways and loss-of-function (#LoF) of tumor suppressors. Our lead program targets Alternative Lengthening of Telomeres (#ALT) through the FANCM protein complex.   Catch one of us at #AACR24: Andree Blaukat (CEO), Katie Chapman (Head of Discovery Biology), Jürgen Moll, PhD (CSO), Laurent Rigoreau (Head of Medicinal Chemistry), Jana Wolf (Discovery Leader), Donata Federici Canova (Discovery Leader), and Joris Schuurmans (Head of Diagnostics).   Email: info@tessellatebio.com   Visit our website: www.tessellatebio.com for further information.   #PrecisonOncology #SyntheticLethality #DrugDiscovery 

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics